Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Here’s Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw strong trading volume on Friday . 1,157,949 shares traded hands during trading, an increase of 44% from the previous session’s volume of 803,468 shares.The stock last traded at $57.26 and had previously closed at $53.36.

Analyst Ratings Changes

Several brokerages recently commented on DNTH. Wedbush reissued an “outperform” rating and set a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Truist Financial increased their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $64.43.

Dianthus Therapeutics Stock Up 2.0%

The stock’s 50 day moving average price is $43.55 and its 200-day moving average price is $34.79. The stock has a market capitalization of $2.33 billion, a PE ratio of -15.64 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 216,538 shares of company stock valued at $8,283,175. 8.15% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. Parkside Financial Bank & Trust increased its holdings in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Tower Research Capital LLC TRC lifted its holdings in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Finally, AlphaQuest LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $94,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.